Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 12.1 USD -0.66% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

P/E
Price to Earnings

-1.4
Current
-7.6
Median
22.1
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-1.4
=
Market Cap
1.2B USD
/
Net Income
-871.3m USD
All Countries
Close
Earnings Growth P/E to Growth
US
Intellia Therapeutics Inc
NASDAQ:NTLA
Average P/E: 212.6
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
60.8
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.3
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
920.3
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.8
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-2.1
2-Years Forward
P/E
-2.1
3-Years Forward
P/E
-2

See Also

Discover More